Recent Study Demonstrates Leveraging ECV-CTA Assessment from Routine TAVR Evaluation Correlates Well with ECV-CMR and Has Significant Methodological Implications

Share Article

Ziosoft Offers One of the Only Commercially Available Solutions for Measuring ECV-CT Plus a Single Platform for Other Cardiac Analyses

In this pilot study using Ziosoft post-processing software, ECV-CTA had an excellent correlation with gold standard ECV-CMR in patients with severe aortic stenosis undergoing TAVR evaluation

A study abstract published at the annual Society of Cardiac Computed Tomography (SCCT) congress last week indicated an excellent correlation of extracellular volume fraction (ECV) computed tomography (CT) with ECV cardiac magnetic resonance (CMR) in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) and had significant methodological implications. The pilot research study from Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital utilized a commonly available prospective ECG-gated acquisition, which provided reliable imaging quality for ECV-CT analysis using Ziosoft, one of the only commercially available ECV-CT solutions.

“In this pilot study, ECV-CTA had an excellent correlation with gold standard ECV-CMR in patients with severe aortic stenosis undergoing TAVR evaluation,” said João Cavalcante, MD, director of Cardiac MRI and Structural CT Labs at Allina Health Minneapolis Heart Institute and medical director of Imaging Core Lab at Minneapolis Heart Institute Foundation. “Ziosoft’s ECV-CT intuitive workflow with co-registration of pre-contrast and delayed acquisitions facilitated the analysis of ECV-CT by the creation of a multisegmented ECV-CT map, which allows for a quick assessment of the extent and magnitude of the problem in this population at risk of developing myocardial fibrosis. This technology helped enable ECV-CT assessment making it a viable, non-invasive approach for non-invasive assessment of myocardial fibrosis and potential pre-screening of Cardiac Amyloidosis during a pre-planning TAVR or post-TAVR procedure.”

CT TAVR planning also can evaluate ECV to indicate the presence of concomitant cardiac amyloidosis, which can be as frequent as 12-15% in this elderly population. With the Ziostation2 CT myocardial ECV application, CT TAVR planning can help analyze CCTA (Coronary CT Angiography) and dual-energy studies for detection of both cardiac amyloidosis and/or myocardial fibrosis in patients undergoing TAVR evaluation.

“With the U.S. performing more than 73,000 TAVR procedures annually, the findings of this study could be significant,” said Rajeev Taitriya, vice president of marketing and business development for Ziosoft. “From one order using one protocol, ZioStation2 offers a single platform to perform analysis for CCTA TAVR with ECV-CT, Additionally, it provides a one-stop shop that can include the evaluation of calcium scoring, function, coronaries and LAAO from the CCTA TAVR protocol. We are pleased to be a part of this and many other studies showing the power of Ziosoft technology.”
The Ziosoft platform also offers its unique PhyZiodynamics 3D/4D solution, as well as the recently introduced Zioflex, a monthly subscription program designed to provide a risk-free introduction to Ziosoft’s many AV clinical applications.

“We have more than 20 years of medical imaging expertise with deep learning to enable accurate evaluations with easy-to-use intuitive tools for efficient and customizable workflows,” said Shusuke Chino, co-founder, and president, Ziosoft. “Working with such outstanding healthcare professionals like Dr.Cavalcante from Minneapolis Heart Institute, we look forward to creating more significant developments to expand our AI-enabled visualization platform.”

About Ziosoft.

Ziosoft provides a comprehensive multi-modality, 3D/4D advanced processing and viewing solution for a wide variety of specialties. Its customizable platform provides an automated workflow to maximize efficiency. It is also a scalable, enterprise platform for "anywhere" accessibility and, as a software-only solution, it is simplified to minimize the cost of ownership. Ziosoft is part of the Los Angeles-based Nantworks a consortium of companies led by Patrick Soon-Shiong, MD, the past founder of Abraxis BioScience, current CEO of Nantworks, founder, executive chairman, and chief science officer for ImmunityBio. He is also the owner of the Los Angeles Times and San Diego Tribune. For further information on Ziosoft, visit

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Laurie Hallwyler
1 6502489081
Email >